Skip to main content

Table 1 Biomarker associations of a PCSK9 gene centric score, effect presented as mean difference (MD) with 95% confidence interval in brackets with the effects scaled to a 1 mmol/L decrease in LDL-C

From: Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

Biomarker Total sample size MD (95% CI)
Lipids related biomarkers
 HDL-C in mmol/L 314,078 0.05 (0.02; 0.07)
 TG in mmol/L 298,069 −0.07 (− 0.12; − 0.01)
 TC in mmol/L 320,170 − 1.06 (− 1.12; − 1.00)
 ApoA1 in g/L 55,477 0.02 (− 0.01; 0.06)
 ApoB in g/L 54,643 −0.20 (− 0.25; − 0.18)
 LP [a] in mg/dL 21,181 −4.12 (−8.62; 0.38)
Safety related biomarkers
 SBP in mmHG 182,487 0.03 (−0.05; 0.10)
 DBP in mmHG 182,497 0.08 (0.001; 0.15)
 CRP in log (mg/L) 91,990 0.03 (−0.07; 0.14)
 IL-6 in log (pmol/L) 22,370 −0.08 (− 0.21; 0.04)
 GGT in log (IU/L) 69,488 0.03 (−0.04; 0.10)
 Fibrinogen in log(g/dL) 63,288 0.02 (−0.01; 0.04)
 Hemoglobin in g/L 52,109 1.16 (−0.38; 2.70)
 ALT in log (IU/L) 83,223 0.03 (−0.02; 0.08)
 AST in log (IU/L) 49,556 0.01 (−0.03; 0.05)
 ALP in log (IU/L) 60,222 −0.06 (− 0.09; − 0.02)
 Creatinine in umol/L 100,206 0.06 (−1.43; 1.55)
  1. Nota bene, TG triglycerides, TC Total cholesterol, ApoA1 Apolipoprotein A1, ApoB Apolipoprotein B, LPa Lipoprotein a, SBP Systolic blood pressure, DBP Diastolic blood pressure, CRP C-reactive protein, IL-6 Interleukin-6, GGT Gamma-glutamyltransferase, ALT Alanine transaminase, AST Aspartate transaminase, ALP Alkaline phosphatase